Proposed Data Collection Submitted for Public Comment and Recommendations, 88620-88621 [2023-28174]
Download as PDF
<![CDATA[
88620
Federal Register / Vol. 88, No. 245 / Friday, December 22, 2023 / Notices
the key elements of a safety station
program so that facility-specific detailed
plans and programs can be developed in
an informed manner. Safety station
programs are voluntary and are not
mandatory for Federal facilities. The
costs and expenses to establish and
operate a safety station program are the
responsibility of the occupant agency or
agencies sponsoring the program and
not GSA or HHS, except to the extent
GSA or HHS, or both, are sponsoring a
program in a facility where they are
occupant agencies.
The importance of keeping opioid
reversal agents easily accessible has
been highlighted by the U.S. Surgeon
General and the Centers for Disease
Control and Prevention (CDC). On April
5, 2018, Surgeon General Jerome Adams
issued an advisory recommending that
more individuals keep naloxone on
hand. The link to the advisory can be
found at https://www.hhs.gov/
surgeongeneral/reports-andpublications/addiction-and-substancemisuse/advisory-on-naloxone/
index.html. On October 5, 2018, the
CDC’s National Institute for
Occupational Safety and Health
(NIOSH) issued the fact sheet ‘‘Using
Naloxone to Reverse Opioid Overdose
in the Workplace: Information for
Employers and Workers’’ to assist
workplace decision makers in
establishing a naloxone availability and
use program. The link to the white
paper can be found at https://
www.cdc.gov/niosh/docs/2019-101/
pdfs/2019-101.pdf. The Surgeon General
advisory and the CDC NIOSH fact sheet
highlight the importance of having
opioid reversal agents in public spaces
for quick access and why they should be
included in an agency’s safety station
program.
Krystal J. Brumfield,
Associate Administrator, Office of
Government-wide Policy, U.S. General
Services Administration.
Rachel L. Levine,
Assistant Secretary for Health, U.S.
Department of Health and Human Services.
[FR Doc. 2023–28207 Filed 12–21–23; 8:45 am]
ddrumheller on DSK120RN23PROD with NOTICES1
BILLING CODE 6820–14–P
VerDate Sep<11>2014
18:10 Dec 21, 2023
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–1074; Docket No. CDC–2023–
0100]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled Colorectal
Cancer Control Program (CRCCP)
Monitoring Activities. CDC is requesting
an Extension to OMB Control No. 0920–
1074 to continue information collection
via an annual survey, a clinic-level data
collection instrument, and a quarterly
recipient-level program update survey.
DATES: CDC must receive written
comments on or before February 20,
2024.
SUMMARY:
You may submit comments,
identified by Docket No. CDC–2023–
0100 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
ADDRESSES:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Telephone: 404–639–7118; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Colorectal Cancer Control Program
(CRCCP) Monitoring Activities (OMB
Control No. 0920–1074, Exp. 03/31/
2024)—Extension—National Center for
Chronic Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Colorectal cancer (CRC) is the second
leading cause of death from cancer in
the United States among cancers that
affect both men and women. There is
substantial evidence that CRC screening
reduces the incidence of, and death
from the disease. Screening for CRC can
detect disease early when treatment is
more effective, and can prevent cancer
by finding and removing precancerous
E:\FR\FM\22DEN1.SGM
22DEN1
88621
Federal Register / Vol. 88, No. 245 / Friday, December 22, 2023 / Notices
polyps. Of individuals diagnosed with
early stage CRC, more than 90% live
five or more years. Despite strong
evidence supporting screening, only
68.8% of adults currently report being
up-to-date with CRC screening as
recommended by the U.S. Preventive
Services Task Force in 2018, with more
than 22 million age-eligible adults
estimated to be untested. To reduce CRC
morbidity, mortality, and associated
costs, use of CRC screening tests must
be increased among age-eligible adults
with the lowest CRC screening rates.
The purpose of the Colorectal Cancer
Control Program (CRCCP) is to partner
with health systems and their
individual primary care clinics to
implement Evidence-based
interventions (EBIs) to increase CRC
screening among defined populations of
adults ages 50–75 that have CRC
screening rates lower than the national,
regional, or local rate. In 2020, CDC
issued the funding opportunity, Public
Health and Health System Partnerships
to Increase Colorectal Cancer Screening
in Clinical Settings (DP20–2002), a 5year cooperative agreement to increase
CRC screening among defined
populations of adults ages 50–75 that
have CRC screening rates lower than the
national, regional, or local rate. DP20–
2002 funds recipients to partner with
health systems and their primary care
clinics to implement multiple EBIs,
partner with organizations to support
implementation of EBIs in those clinics,
and collect high-quality clinic-level data
when a clinic is recruited to participate
(baseline) and annually thereafter to
monitor EBI implementation and assess
screening rate changes. DP20–2002 also
requires recipients to conduct a formal
capacity/readiness assessment of
potential clinics to implement EBIs, use
assessment findings to select
appropriate EBIs for implementation,
and provide clinics with limited
financial resources to support follow-up
colonoscopies for under- and uninsured
patients after an abnormal CRC
screening test.
CDC proposes three information
collections—the Annual Awardee
Survey, the Clinic-Level Data Collection
Instrument, and the Quarterly Program
Update—to reflect the strategies and
objectives detailed in DP20–2002. CDC
will conduct data collections for each of
these three proposed activities among
all 35 recipients following the end of
each program year which runs from July
1–June 30.
The Annual Awardee Survey assesses:
(1) program management; (2) clinic
readiness assessment activities; (3) data
management; (4) technical assistance
(TA) needs; (5) partnerships; and (6) the
effect of COVID–19 on CRC
implementation at the recipient level.
The Clinic-level Information
Collection Instrument assesses: (1)
health system and clinic characteristics;
(2) program reach; (3) CRC screening
practices and outcomes; (4) clinics’
quality improvement and monitoring
activities; (5) EBI implementation; and
(6) additional factors that affect EBI
implementation over time.
The Quarterly Program Update will
collect standardized recipient-level
information on aspects of program
management, including: (1) quarterly
program expenditures; (2) current staff
vacancies; (3) program successes and
challenges; (4) current TA needs; and (5)
the effect of COVID–19 on CRCCP
implementation at the recipient level.
These data are collected quarterly to
enable rapid reporting of programmatic
information to support CDC program
consultants in providing tailored and
meaningful TA.
This information collection enables
CDC to gauge progress in meeting
CRCCP program goals and monitor
implementation activities, evaluate
outcomes, and identify recipients’ TA
needs. In addition, data collected will
inform program improvement and help
identify successful activities that need
to be maintained, replicated, or
expanded. CDC is requesting a 3-year
Extension to the Colorectal Cancer
Control Program (CRCCP) Monitoring
Activities collection (OMB No. 0920–
1074). The total estimated annualized
burden is 760 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
CRCCP Annual Awardee Survey .........................................
CRCCP Clinic-level Information Collection Instrument ........
CRCCP Quarterly Program Update .....................................
35
35
35
1
24
4
15/60
50/60
22/60
9
700
51
...............................................................................................
....................
........................
....................
760
Form name
CRCCP Recipients .......
Total .......................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2023–28174 Filed 12–21–23; 8:45 am]
ddrumheller on DSK120RN23PROD with NOTICES1
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–8003]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
SUMMARY:
VerDate Sep<11>2014
Average
burden per
response
(in hr)
Number of
respondents
Type of respondent
18:10 Dec 21, 2023
Jkt 262001
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Total
burden
(in hr)
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, and to allow
a second opportunity for public
comment on the notice. Interested
persons are invited to send comments
regarding the burden estimate or any
other aspect of this collection of
information, including the necessity and
utility of the proposed information
collection for the proper performance of
E:\FR\FM\22DEN1.SGM
22DEN1
]]>Agencies
[Federal Register Volume 88, Number 245 (Friday, December 22, 2023)]
[Notices]
[Pages 88620-88621]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-28174]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-1074; Docket No. CDC-2023-0100]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on a continuing information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on a proposed information collection project
titled Colorectal Cancer Control Program (CRCCP) Monitoring Activities.
CDC is requesting an Extension to OMB Control No. 0920-1074 to continue
information collection via an annual survey, a clinic-level data
collection instrument, and a quarterly recipient-level program update
survey.
DATES: CDC must receive written comments on or before February 20,
2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2023-
0100 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (www.regulations.gov) or by U.S. mail to the address listed
above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7118;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
Colorectal Cancer Control Program (CRCCP) Monitoring Activities
(OMB Control No. 0920-1074, Exp. 03/31/2024)--Extension--National
Center for Chronic Disease Prevention and Health Promotion (NCCDPHP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Colorectal cancer (CRC) is the second leading cause of death from
cancer in the United States among cancers that affect both men and
women. There is substantial evidence that CRC screening reduces the
incidence of, and death from the disease. Screening for CRC can detect
disease early when treatment is more effective, and can prevent cancer
by finding and removing precancerous
[[Page 88621]]
polyps. Of individuals diagnosed with early stage CRC, more than 90%
live five or more years. Despite strong evidence supporting screening,
only 68.8% of adults currently report being up-to-date with CRC
screening as recommended by the U.S. Preventive Services Task Force in
2018, with more than 22 million age-eligible adults estimated to be
untested. To reduce CRC morbidity, mortality, and associated costs, use
of CRC screening tests must be increased among age-eligible adults with
the lowest CRC screening rates.
The purpose of the Colorectal Cancer Control Program (CRCCP) is to
partner with health systems and their individual primary care clinics
to implement Evidence-based interventions (EBIs) to increase CRC
screening among defined populations of adults ages 50-75 that have CRC
screening rates lower than the national, regional, or local rate. In
2020, CDC issued the funding opportunity, Public Health and Health
System Partnerships to Increase Colorectal Cancer Screening in Clinical
Settings (DP20-2002), a 5-year cooperative agreement to increase CRC
screening among defined populations of adults ages 50-75 that have CRC
screening rates lower than the national, regional, or local rate. DP20-
2002 funds recipients to partner with health systems and their primary
care clinics to implement multiple EBIs, partner with organizations to
support implementation of EBIs in those clinics, and collect high-
quality clinic-level data when a clinic is recruited to participate
(baseline) and annually thereafter to monitor EBI implementation and
assess screening rate changes. DP20-2002 also requires recipients to
conduct a formal capacity/readiness assessment of potential clinics to
implement EBIs, use assessment findings to select appropriate EBIs for
implementation, and provide clinics with limited financial resources to
support follow-up colonoscopies for under- and uninsured patients after
an abnormal CRC screening test.
CDC proposes three information collections--the Annual Awardee
Survey, the Clinic-Level Data Collection Instrument, and the Quarterly
Program Update--to reflect the strategies and objectives detailed in
DP20-2002. CDC will conduct data collections for each of these three
proposed activities among all 35 recipients following the end of each
program year which runs from July 1-June 30.
The Annual Awardee Survey assesses: (1) program management; (2)
clinic readiness assessment activities; (3) data management; (4)
technical assistance (TA) needs; (5) partnerships; and (6) the effect
of COVID-19 on CRC implementation at the recipient level.
The Clinic-level Information Collection Instrument assesses: (1)
health system and clinic characteristics; (2) program reach; (3) CRC
screening practices and outcomes; (4) clinics' quality improvement and
monitoring activities; (5) EBI implementation; and (6) additional
factors that affect EBI implementation over time.
The Quarterly Program Update will collect standardized recipient-
level information on aspects of program management, including: (1)
quarterly program expenditures; (2) current staff vacancies; (3)
program successes and challenges; (4) current TA needs; and (5) the
effect of COVID-19 on CRCCP implementation at the recipient level.
These data are collected quarterly to enable rapid reporting of
programmatic information to support CDC program consultants in
providing tailored and meaningful TA.
This information collection enables CDC to gauge progress in
meeting CRCCP program goals and monitor implementation activities,
evaluate outcomes, and identify recipients' TA needs. In addition, data
collected will inform program improvement and help identify successful
activities that need to be maintained, replicated, or expanded. CDC is
requesting a 3-year Extension to the Colorectal Cancer Control Program
(CRCCP) Monitoring Activities collection (OMB No. 0920-1074). The total
estimated annualized burden is 760 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total
Type of respondent Form name respondents responses per response burden
respondent (in hr) (in hr)
----------------------------------------------------------------------------------------------------------------
CRCCP Recipients................. CRCCP Annual Awardee 35 1 15/60 9
Survey.
CRCCP Clinic-level 35 24 50/60 700
Information Collection
Instrument.
CRCCP Quarterly Program 35 4 22/60 51
Update.
----------------------------------------------------
Total........................ ........................ ........... .............. ........... 760
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2023-28174 Filed 12-21-23; 8:45 am]
BILLING CODE 4163-18-P
